Skip Navigation

Journal of Gerontology 1991 46(6):P372-P377; doi:10.1093/geronj/46.6.P372
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Teri, L.
Right arrow Articles by Raskind, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 The Gerontological Society of America

Imipramine in the Treatment of Depressed Alzheimer's Patients: Impact on Cognition

Linda Teri1, Burton V. Reifler1, Richard C. Veith1,3, Robert Barnes1,3, Emily White2, Pamela McLean1 and Murray Raskind1

1 Department of Psychiatry and Behavioral Sciences, University of Washington
2 Department of Epidemiology, University of Washington
3 Geriatric Research, Education and Clinical Center, Seattle Veterans Administration Medical Center


  Abstract

A double-blind study evaluated the impact of imipramine on cognitive function in 61 patients with Alzheimer's disease. Twenty-eight patients had coexistent depression and dementia; 33 had dementia only. All were randomly assigned to an 8-week trial of imipramine or placebo. For both depressed and nondepressed subjects, the effect of imipramine on cognition was minimal. A subtle decrement in general cognitive function was evident in those treated with imipramine, as compared with those treated with placebo. No effects were observed on memory. Clinicians are advised that very low doses of imipramine (25 mg/daily) may be tolerated in depressed Alzheimer patients, but that cognitive changes do occur in some patients and should be carefully monitored.

Received for publication February 9, 1989. Accepted for publication February 8, 1990.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Geriatr Psychiatry NeurolHome page
J. O. Brooks and J. C. Hoblyn
Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214.
[Abstract] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
P. M. Doraiswamy, K. R. R. Krishnan, T. Oxman, L. R. Jenkyn, D. J. Coffey, T. Burt, and C. M. Clary
Does Antidepressant Therapy Improve Cognition in Elderly Depressed Patients?
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1137 - 1144.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.